This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elkin, E. B. Articles by Weeks, J. C. Search for Related Content PubMed PubMed Citation Articles by Elkin, E. B. Articles by Weeks, J. C.

HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis

From the Harvard University Center for Risk Analysis and School of Public Health, Cambridge; the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA

Address reprint requests to Elena B. Elkin, PhD, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021; e-mail: elkine{at}mskcc.org

PURPOSE: Trastuzumab therapy has been shown to benefit metastatic breast cancer patients whose tumors exhibit HER-2 protein overexpression or gene amplification. Several tests of varying accuracy and cost are available to identify candidates for trastuzumab. We estimated the cost-effectiveness of alternative HER-2 testing and trastuzumab treatment strategies.

PATIENTS AND METHODS: We performed a decision analysis using a state-transition model to simulate clinical practice in a hypothetical cohort of 65-year-old metastatic breast cancer patients. Outcomes were quality-adjusted life-years (QALYs), lifetime cost, and incremental cost-effectiveness ratio (ICER). Interventions included testing with the HercepTest (DAKO, Carpinteria, CA) immunohistochemical assay alone, fluorescence in situ hybridization (FISH) alone, and both tests, followed by trastuzumab and chemotherapy for patients with positive test results and chemotherapy alone for patients with negative test results.

RESULTS: In the base case, initial HercepTest with FISH confirmation of all positive results had an ICER of $125,000 per QALY gained. The incremental cost-effectiveness of initial FISH was $145,000 per QALY gained. Other strategies yielded the same or poorer effectiveness at a higher cost, or lower effectiveness at a lower cost, but with a less favorable ICER. These findings persisted under a range of assumptions, and only changes in test characteristics substantially altered results.

CONCLUSION: It is more cost-effective to use FISH alone or as confirmation of all positive HercepTest results, rather than using FISH to confirm only weakly positive results or using HercepTest alone. When multiple tests are available to identify treatment candidates, test characteristics may have a substantial impact on the aggregate costs and effectiveness of treatment.

Supported by a grant (T15LMO7092) from the National Library of Medicine Research Training Program in Medical Informatics.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer Ann. Onc., March 1, 2008; 19(3): 487 - 495. [Abstract] [Full Text] [PDF]

				A. Glazyrin, X. Shen, V. Blanc, and J. F. Eliason Direct Detection of Herceptin/Trastuzumab Binding on Breast Tissue Sections J. Histochem. Cytochem., January 1, 2007; 55(1): 25 - 33. [Abstract] [Full Text] [PDF]

				P. D. Vermeer, L. Panko, P. Karp, J. H. Lee, and J. Zabner Differentiation of human airway epithelia is dependent on erbB2 Am J Physiol Lung Cell Mol Physiol, August 1, 2006; 291(2): L175 - L180. [Abstract] [Full Text] [PDF]

				T. Tanvetyanon HER-2 and Fluorescent In Situ Hybridization to Evaluate Breast Cancer JAMA, July 21, 2004; 292(3): 328 - 328. [Full Text] [PDF]